Leman Biotech Initiates Clinical Study of META 10-19 in Relapsed/Refractory Autoimmune Hemolytic Anemia (AIHA)

10.14
2026

Collaboration with the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences expands the clinical footprint of the META 10 metabolic reprogramming platform into refractory autoimmune blood disorders.

 

October 12, 2026 – Leman Biotech Co., Ltd., a clinical-stage biotechnology company advancing next-generation immunotherapies, today announced the initiation of an investigator-initiated trial (IIT) evaluating META 10-19 for the treatment of relapsed or refractory (R/R) autoimmune hemolytic anemia (AIHA).

 

The study is being conducted in collaboration with the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), under the leadership of Principal Investigator Dr. Jun Shi, Chief Physician and Vice President of the Institute. The kick-off meeting aligned the clinical and research teams on study execution standards, marking the official transition of the study into the patient enrollment phase.

 

Regulatory Milestone and Study Initiation

 

The clinical study has been officially accepted under the 11th batch of the Biomedical New Technology Clinical Research Filing system by the National Health Commission (NHC) of China. Acceptance of the filing allows the study to proceed to patient enrollment and provides a solid foundation for high-quality, compliant clinical execution.

 

Addressing a Significant Unmet Need in Autoimmune Hematology

 

AIHA is a challenging autoimmune hematological disorder characterized by autoantibody-mediated destruction of red blood cells. Patients with R/R AIHA who have exhausted standard therapies—including corticosteroids and conventional immunosuppressants—often face frequent relapses, inadequate responses, poor treatment tolerance, and limited therapeutic options.

 

While conventional therapies rely largely on long-term, non-specific immunosuppression, targeted cell therapy is emerging as a paradigm-shifting approach. By deeply depleting autoreactive B cells, CD19-directed CAR-T therapies offer the potential for an “immune reset” and durable, treatment-free remission in severe, refractory autoimmune diseases.

 

Expanding the META 10 Platform's Autoimmune Footprint

 

META 10-19 is built on Leman Biotech’s proprietary META 10 platform, originating from foundational research at the École Polytechnique Fédérale de Lausanne (EPFL). By employing IL-10-mediated metabolic reprogramming, the platform shifts CAR-T cells away from terminal exhaustion toward sustained proliferation and activation, generating a robust stem-like memory T-cell phenotype.

 

This new AIHA study further broadens the clinical development of the META 10 platform in autoimmune diseases. To date, META 10-19 has secured two Investigational New Drug (IND) clearances from the U.S. FDA and three IND clearances from China’s NMPA, spanning indications in B-cell hematological malignancies and systemic lupus erythematosus (SLE). The initiation of the AIHA study underscores the platform's versatility and its potential to address a wider spectrum of refractory autoimmune conditions.

 

Outlook

 

With the study now open for patient enrollment, Leman Biotech will work closely with the Institute of Hematology & Blood Diseases Hospital to evaluate the safety and preliminary efficacy of META 10-19 in R/R AIHA, and will continue to advance the clinical development of its META 10 platform across autoimmune diseases, with the goal of delivering safer, more effective, and more accessible cell therapies to patients worldwide.

 

About META 10-19
 

META 10-19 is a novel CD19-targeted CAR-T therapy developed by Leman Biotech based on META 10, its breakthrough metabolic reprogramming technology originating from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland. META 10 overcomes T-cell exhaustion through IL-10-mediated metabolic enhancement, enabling potent anti-tumor activity at ultra-low doses and potentially eliminating the need for toxic lymphodepleting chemotherapy in select indications. META 10-19 has received IND clearance from both the U.S. FDA and China’s NMPA for hematological malignancies and autoimmune disease.

 

About the Institute of Hematology and Blood Diseases Hospital, CAMS 


The Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, is the premier national center for blood disease research and treatment in China. It serves as the National Clinical Research Center for Blood Diseases and is globally recognized for its leadership in hematology, regenerative medicine, and red blood cell disorders.

 

About Leman Biotech


Leman Biotech is a clinical-stage biotechnology company dedicated to developing next-generation cancer and autoimmune immunotherapies through its proprietary META 10 metabolic reprogramming platform. By targeting the metabolic drivers of T-cell exhaustion, the company aims to deliver more durable, safer, and more accessible cell therapy solutions. Leman Biotech's pipeline includes investigational CAR-T and TIL-based therapies for hematological malignancies, solid tumors, and autoimmune diseases.